Progenics Pharmaceuticals, Inc. - SWOT Analysis

Summary

Datamonitor's Progenics Pharmaceuticals - SWOT Analysis company profile is the essential source for top-level company data and information. Progenics Pharmaceuticals - SWOT Analysis examines the company's key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strategy.

Progenics Pharmaceuticals (Progenics) is a biopharmaceutical company engaged in the development and commercialization of innovative therapeutic products to meet the medical needs in the areas of gastroenterology, virology and oncology. Progenics, in collaboration with Wyeth, is developing Relistor (methylnaltrexone bromide) for the treatment of opioid-induced side effects. The subcutaneous form of Relistor is approved for use in the US, Canada and European Union member states as well as in Iceland, Norway and Liechtenstein. Progenics is headquartered in Tarrytown, New York and employed 245 people as of December 2007. The company recorded revenues of $76 million during the financial year (FY) ended December 2007, an increase of 8.2% over FY2006. The increase was primarily attributable to increased research revenues from Wyeth related to the development of subcutaneous, intravenous and oral formulations of methylnaltrexone. The operating loss of the company was $51 million during FY2007, as compared to an operating loss of $29 million in FY2006. The net loss was $44 million in FY2007, as compared to a net loss of $22 million in FY2006.

Scope of the Report

• Provides all the crucial information on Progenics Pharmaceuticals required for business and competitor intelligence needs
• Contains a study of the major internal and external factors affecting Progenics Pharmaceuticals in the form of a SWOT analysis as well as a breakdown and examination of leading product revenue streams of Progenics Pharmaceuticals
• Data is supplemented with details on Progenics Pharmaceuticals history, key executives, business description, locations and subsidiaries as well as a list of products and services and the latest available statement from Progenics Pharmaceuticals

Reasons to Purchase

• Support sales activities by understanding your customers' businesses better
• Qualify prospective partners and suppliers
• Keep fully up to date on your competitors' business structure, strategy and prospects
• Obtain the most up to date company information available

This report covers the following industry codes:

SIC Code: 2834

NAICS Code: 325412

Contents

• This product typically includes the following sections:
• SWOT COMPANY PROFILE: PROGENICS PHARMACEUTICALS
  • Key Facts: Progenics Pharmaceuticals
  • Company Overview: Progenics Pharmaceuticals
  • Business Description: Progenics Pharmaceuticals
  • Company History: Progenics Pharmaceuticals
  • Key Employees: Progenics Pharmaceuticals
  • Key Employee Biographies: Progenics Pharmaceuticals
  • Products & Services Listing: Progenics Pharmaceuticals
  • Products & Services Analysis: Progenics Pharmaceuticals
• SWOT analysis: Progenics Pharmaceuticals
  • Strengths: Progenics Pharmaceuticals
  • Weaknesses: Progenics Pharmaceuticals
  • Opportunities: Progenics Pharmaceuticals
  • Threats: Progenics Pharmaceuticals
• Company View: Progenics Pharmaceuticals
  • Top Competitors: Progenics Pharmaceuticals
  • Location and Subsidiary: Progenics Pharmaceuticals
  • Head Office: Progenics Pharmaceuticals
  • Other Locations and Subsidiaries: Progenics Pharmaceuticals